GlassScriptPhysician profile
Ritu Badola
NPI 1376529784
$2,847.65
in general payments reported to CMS, 2019-2025
20 companies · $103 in 2025
The $103 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $620 · 2020: $471 · 2021: $722 · 2022: $715 · 2023: $217 · 2025: $103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $320.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $320.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $412.31 | 2019-2023 | |
| Novo Nordisk INC | $370.96 | 2019-2022 | |
| Glaxosmithkline, LLC. | $304.19 | 2019-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $294.36 | 2020-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $249.44 | 2019-2023 | |
| Amarin Pharma, INC. | $221.99 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $211.90 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $185.56 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $182.83 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $126.67 | 2019-2023 | Xarelto |
| Esperion Therapeutics, INC. | $80.84 | 2020-2021 | |
| Exact Sciences Corporation | $40.82 | 2025 | The Cologuard Plus Collection Kit |
| Abbott Laboratories | $35.71 | 2021 | |
| Amgen INC. | $30.44 | 2025 | Krystexxa, Repatha |
| Abbvie INC. | $20.52 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $19.04 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.22 | 2019 | |
| Lilly USA, LLC | $16.42 | 2021 | |
| Vistapharm, INC. | $13.79 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $12.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ritu Badola listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.